Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
At least 5 rolling or boxcar-type acne scars in total within the predefined assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 420
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing a new gel called ELAPR002f to help fill in and smooth out indented acne scars on the face. It targets adults with noticeable acne scars who haven't had success with other treatments. The gel works by filling in the scarred areas to make the skin look smoother. Participants will receive multiple treatments and be monitored for an extended period.
Who is the study for?
This trial is for adults in good health who want to improve moderate to severe atrophic acne scars on both cheeks. They must not have an active COVID-19 infection and should have at least 5 rolling or boxcar-type scars in areas of otherwise healthy skin.
What is being tested?
The study compares the safety and effectiveness of ELAPR002f injectable gel versus a saline control in treating facial atrophic acne scars. Participants will be randomly assigned to one of these treatments, with a higher chance of receiving the gel.
What are the potential side effects?
Potential side effects may include reactions at the injection site such as redness, swelling, pain, bruising, bleeding or itching. There might also be general discomfort associated with intradermal injections.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have at least 5 rolling or boxcar acne scars on my cheek.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to day 420
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 420
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change from Baseline Procedure Pain
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements
+6 moreSecondary study objectives
Change from Baseline on the Overall Score of ACNE-Q - Appearance-Related Distress
Change from Baseline on the Overall Score of ACNE-Q Acne Scars Questionnaire
Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Saline Active ControlExperimental Treatment1 Intervention
Participants will receive 3 treatments of Saline Active Control into the cheek area on each side of the face.
Group II: ELAPR002f Injectable GelExperimental Treatment1 Intervention
Participants will receive 3 treatments of ELAPR002f injectable gel into the cheek area on each side of the face.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for atrophic acne scars, such as injectable fillers like hyaluronic acid, work by providing an immediate space-occupying effect that fills in the indented scar tissue, creating a smoother skin surface. This volumizing effect elevates the depressed areas, making the scars less noticeable.
Some fillers also stimulate collagen production, which can improve skin texture and elasticity over time. These mechanisms are important for atrophic acne scar patients as they offer both immediate and long-term improvements in skin appearance, enhancing self-esteem and quality of life.
Resistance of rapidly expanded random skin flaps to bacterial invasion.A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin.Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice.
Resistance of rapidly expanded random skin flaps to bacterial invasion.A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin.Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice.
Find a Location
Who is running the clinical trial?
AbbVieLead Sponsor
1,022 Previous Clinical Trials
520,023 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
443 Previous Clinical Trials
160,509 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger